Prostate cancer targeted multifunctionalized graphene oxide for magnetic resonance imaging and drug delivery

详细信息    查看全文

• 作者：Linlin Guo^a ; Haili Shi^a ; Huixia Wu^a ; ^{wuhuixia@shnu.edu.cn" class="auth_mail" title="E-mail the corresponding author} ; Yixue Zhang^a ; Xue Wang^a ; Dongmei Wu^b ; Lu An^a ; Shiping Yang^a
• 刊名：Carbon
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：107
• 期：Complete
• 页码：87-99
• 全文大小：5538 K

文摘

Dendrimers capped with amino groups (DEN) are grafted to graphene oxide (GO) nanosheets for subsequent functionalization of GO with gadolinium diethylene triamine pentaacetate (Gd-DTPA) and prostate stem cell antigen (PSCA) monoclonal antibody (mAb). The as-prepared GO-DEN(Gd-DTPA)-mAb exhibits very low cytotoxicity, negligible hemolytic activity, and no perceptible toxic effects in mice. GO-DEN(Gd-DTPA)-mAb can specifically target PSCA over-expressed cancer cells to give a significant T₁-weighted contrast enhancement effect. The in vivo magnetic resonance imaging results indicate that GO-DEN(Gd-DTPA)-mAb can be used as a targeted contrast agent for prostate tumor imaging. GO-DEN(Gd-DTPA)-mAb can be efficiently loaded with doxorubicin hydrochloride (DOX), and the resulting GO-DEN(Gd-DTPA)-mAb/DOX exhibits enhanced cytotoxicity to PC-3 cells due to good targeting performance. By following the PC-3 tumor growth in mouse model after intravenous administration of GO-DEN(Gd-DTPA)-mAb/DOX, it is demonstrated that GO-DEN(Gd-DTPA)-mAb can targetedly deliver anticancer drugs to malignant prostate tumors and inhibit tumor growth.